Stay updated with breaking news from Aurix system. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HOUSTON, June 22, 2023 (GLOBE NEWSWIRE) Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare . ....
The following discussion and analysis of the Company s financial condition and results of operations should be read in conjunction with the financial statements and related notes appearing elsewhere. | April 17, 2023 ....
HOUSTON, Feb. 04, 2022 Nuo Therapeutics, Inc. announced that it is aware of an unsolicited “mini-tender” offer by Alternative Liquidity Index, LP to purchase up to 1,820,000 shares. ....
Nuo Therapeutics Responds to Mini-Tender Offer forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Share this article HOUSTON, April 20, 2021 /PRNewswire/ Nuo Therapeutics, Inc. (OTC Pink: AURX) ( Nuo or the Company ), today announced the recent publication of the final decision memo for Autologous Blood-Derived Products for Chronic Non-Healing Wounds (CAG-00190R4). On April 13, 2021, Centers for Medicare & Medicaid Services (CMS) concluded in its final coverage decision memo (available at the URL at the bottom of this release) that Medicare will cover autologous platelet-rich plasma (PRP) for treatment of chronic non-healing diabetic wounds (DFUs) under section 1862(a)(1)(A) of the Social Security Act. This final decision follows the favorable proposed decision memo which was published December 21, 2020 and followed by a thirty-day public comment period. In its final decision memo, CMS concluded that the coverage for DFUs would be for a duration of 20 weeks and limited to devices whose FDA cleared indications include the management of exuding cutaneous woun ....